Should you buy Immatics (IMTX)?
Updated
Immatics is a pre-revenue biotech with quality far below minimum standards, a Piotroski F-Score of 2 out of 9, and 3 of its past 4 quarters delivered misses; analysts nonetheless project approximately 73% upside from current levels, offering a highly asymmetric but deeply speculative setup where execution risk is the dominant variable.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Analysts project roughly 99% upside from current levels and the risk/reward ratio is approximately 10.5-to-1 in favor of buyers, suggesting the market is materially discounting the potential value of the clinical pipeline relative to analyst assessments. Sentiment breakdown | The share price appreciates by more than 40% from current levels over 12 months as clinical catalysts reduce uncertainty. | →Stable |
| CounterAnalyst coverage is noted as light, which reduces the reliability of the consensus; with 3 misses in 4 quarters and quality far below the minimum floor, the high price target may reflect optimism about a pipeline whose execution history has been consistently disappointing. | ||
Free cash flow is negative at 297% of revenue, indicating the company is burning cash at nearly three times its current revenue base and is entirely dependent on capital markets access to sustain operations. Quality breakdown | Cash burn as a percentage of revenue remains above 200% over the next 4 reported quarters, confirming the structural nature of the capital dependency. | →Stable |
| CounterPre-clinical and early clinical-stage biotechs routinely burn cash at multiples of revenue; the burn rate in isolation says little about whether the investment is appropriate for the stage of development, and the company's liquidity position indicates adequate near-term runway. | ||
Three of the past four reported quarters were misses — including the most recent at -15.5% and a severe miss of -88.3% in the oldest quarter — with only a single 29.2% beat, indicating persistently poor alignment between actual results and consensus expectations. Earnings | Average quarterly EPS surprise remains below -5% over the next 2 reported quarters, sustaining the pattern. | →Stable |
| CounterEPS misses at pre-revenue biotechs are driven by R&D spending variability, which can be lumpy and hard to forecast; the one 29.2% beat in the record demonstrates that positive surprises are achievable when spend timing is favorable. | ||
Analysts project roughly 99% upside from current levels and the risk/reward ratio is approximately 10.5-to-1 in favor of buyers, suggesting the market is materially discounting the potential value of the clinical pipeline relative to analyst assessments.
→Stable- Expectation
- The share price appreciates by more than 40% from current levels over 12 months as clinical catalysts reduce uncertainty.
CounterAnalyst coverage is noted as light, which reduces the reliability of the consensus; with 3 misses in 4 quarters and quality far below the minimum floor, the high price target may reflect optimism about a pipeline whose execution history has been consistently disappointing.
Free cash flow is negative at 297% of revenue, indicating the company is burning cash at nearly three times its current revenue base and is entirely dependent on capital markets access to sustain operations.
→Stable- Expectation
- Cash burn as a percentage of revenue remains above 200% over the next 4 reported quarters, confirming the structural nature of the capital dependency.
CounterPre-clinical and early clinical-stage biotechs routinely burn cash at multiples of revenue; the burn rate in isolation says little about whether the investment is appropriate for the stage of development, and the company's liquidity position indicates adequate near-term runway.
Three of the past four reported quarters were misses — including the most recent at -15.5% and a severe miss of -88.3% in the oldest quarter — with only a single 29.2% beat, indicating persistently poor alignment between actual results and consensus expectations.
→Stable- Expectation
- Average quarterly EPS surprise remains below -5% over the next 2 reported quarters, sustaining the pattern.
CounterEPS misses at pre-revenue biotechs are driven by R&D spending variability, which can be lumpy and hard to forecast; the one 29.2% beat in the record demonstrates that positive surprises are achievable when spend timing is favorable.
▸ Show 1 more pillar▾ Show fewer
A Piotroski F-Score of 2 out of 9 — among the weakest possible readings — alongside near-zero across all profitability and return metrics signals broad-based financial weakness that goes beyond the expected cash burn of a typical early-stage biotech.
→Stable- Expectation
- Piotroski F-Score remains below 4 for the next 2 consecutive reported periods, confirming the structural nature of the financial weakness.
CounterThe Piotroski score is calibrated for mature businesses with operating history; at a pre-revenue clinical-stage company where profitability metrics are by design zero, the score mechanically zeroes out on multiple dimensions and may not meaningfully distinguish distress from ordinary developmental-stage economics.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Free cash flow is negative at 297% of revenue, indicating the company is burning cash at nearly three times its current revenue base and is entirely dependent on capital markets access to sustain operations.
Trip ifFCF deficit compresses to less than 100% of revenue for 2 consecutive reported quarters.
- P2Three of the past four reported quarters were misses — including the most recent at -15.5% and a severe miss of -88.3% in the oldest quarter — with only a single 29.2% beat, indicating persistently poor alignment between actual results and consensus expectations.
Trip ifAverage quarterly EPS surprise exceeds 0% for 2 consecutive reported quarters.
- P3Analysts project roughly 99% upside from current levels and the risk/reward ratio is approximately 10.5-to-1 in favor of buyers, suggesting the market is materially discounting the potential value of the clinical pipeline relative to analyst assessments.
Trip ifAnalyst consensus price target falls below $12.00 for 2 consecutive months.
- P4A Piotroski F-Score of 2 out of 9 — among the weakest possible readings — alongside near-zero across all profitability and return metrics signals broad-based financial weakness that goes beyond the expected cash burn of a typical early-stage biotech.
Trip ifPiotroski F-Score rises above 5 out of 9 for 2 consecutive reported periods.
How the engine reached this verdict
TrendMatrix's engine output for Immatics N.V. (IMTX) is SELL_IF_HOLDING with medium conviction, score 4.4/10 at $10.15. An L1 hard-floor gate blocked the positive-verdict path — Quality below minimum threshold; dimensional pillars cannot lift the engine output above the verdict floor while the L1 gate is active.
The engine's exit framework anchors to a tactical sell band near $10.15, with structural invalidation at $9.46. The asymmetric R:R against a reversal hypothesis is 8.66 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bear side: Quality below floor (1.2 < 4.0). Active engine warnings: Quality below floor (1.2 < 4.0).
SELL output reflects multiple gate failures; recovery requires a confluence of those gates re-clearing, not a single dimension move.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates IMTX — 10-dimension breakdown →
Bear case
- ▸Quality below floor (1.2 < 4.0)